Syntara

Syntara ROCE

The Return on Capital Employed (ROCE) of Syntara (SNT.AX) as of Oct 22, 2026 is -100.85 %. In the previous year, Return on Capital Employed (ROCE) was -138.28 % — a change of -27.07% (higher).

ROCE

-100.85 %

YoY

-27.07%

Last updated:

In 2026, Syntara's return on capital employed (ROCE) was -100.85 %, a -27.07% increase from the -138.28 % ROCE in the previous year.

The Syntara ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
-130.88 AUD
Jan 1, 2020
-1,109.64 AUD
Jan 1, 2021
-800.28 AUD
Jan 1, 2022
-183.58 AUD
Jan 1, 2023
-195.53 AUD
Jan 1, 2024
-300.47 AUD
Jan 1, 2025
-138.28 AUD
Jan 1, 2026
-100.85 AUD
The Syntara ROCE history
YEARROCEYoY
-100.85 %-27.07%
-138.28 %-53.98%
-300.47 %+53.67%
-195.53 %+6.51%
-183.58 %-77.06%
-800.28 %-27.88%
-1,109.64 %+747.81%
-130.88 %-308.39%
62.81 %-112.48%
-503.35 %+462.04%
-89.56 %-301.50%
44.45 %-122.54%
-197.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Syntara Stock analysis

What does Syntara do? Syntara Ltd generates revenue through the development and commercialization of pharmaceutical products targeting blood-related cancers and fibrotic diseases. Its lead candidate PXS-5505 is designed for myelofibrosis, a bone marrow cancer causing blood cell loss, while PXS-4728 serves as an SSAO/MAOB inhibitor for sleep disorders and neurodegenerative diseases. The company also markets Bronchitol for cystic fibrosis and Aridol as a lung function test, focusing on respiratory and fibrotic conditions. These products are developed through Syntara's drug discovery engine centered on amine oxidase inhibitors and pan-LOX inhibitors. The company's primary customers are healthcare providers and patients seeking treatments for myelofibrosis, fibrotic diseases, and respiratory conditions. Syntara's drug candidates target specific medical segments including oncology for blood cancers, neurology for Parkinson's disease progression, and respiratory care for cystic fibrosis. The firm advances its pipeline through clinical-stage development, leveraging its expertise in amine oxidase inhibitors to address unmet medical needs in these therapeutic areas. Syntara Limited, formerly Pharmaxis Ltd, operates as a clinical-stage drug development company with a focus on blood-related cancers. Its product portfolio includes PXS-5505 for myelofibrosis, PXS-4728 for neurodegenerative diseases, Bronchitol for cystic fibrosis, and Aridol for lung function testing. The company's revenue streams derive from the advancement of these drug candidates through clinical trials and potential future commercialization, with no indication of current commercial sales in the provided description. Syntara is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Syntara's Return on Capital Employed (ROCE)

Syntara's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Syntara's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Syntara's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Syntara’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Syntara stock

Return on Capital Employed (ROCE) of Syntara is -100.85 % in 2026.

Return on Capital Employed (ROCE) of Syntara changed from -138.28 % to -100.85 %, representing a -27.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Syntara since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Syntara with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Syntara

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Syntara